UNSPSC 51122601: Aspirin/pravastatin

This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class CV350. This VA Drug Class (CV350) classifies this compound as belonging to the group ANTILIPEMIC AGENTS.

UNSPSC 51122601 Aspirin/pravastatin is a Commodity code covering individual pharmaceutical products and active pharmaceutical ingredients that state and local health agencies, emergency services departments, and cooperative purchasing alliances procure for emergency medical response, public health programs, and institutional healthcare delivery. State and local buyers under this code include municipal fire and rescue departments, state health and human services agencies, and multistate cooperative purchasing organizations. The scope of work encompasses supply of specific pharmaceutical products meeting FDA requirements, cGMP certification, Drug Supply Chain Security Act compliance, and contractual relationships with authorized wholesalers or direct distribution channels, with vendors responsible for maintaining expiration-date warranties, arranging replacement of expired stock, and submitting comprehensive product documentation including National Drug Codes and Safety Data Sheets compliant with OSHA standards.

Recent activity shows geographic spread across Florida, Texas, and Minnesota, with issuers ranging from municipal purchasing departments to state health agencies and regional cooperative procurement alliances. The City of Tampa's Purchasing Department issued IFB No. 26P00188 on April 24, 2026, seeking Advanced Life Support Medications including labetalol, epinephrine, adenosine, and diltiazem for Tampa Fire Rescue, with bids due April 8, 2026, a one-year contract term, and an estimated value of $40,000.00 that included a 5 percent SLBE bid discount. The Minnesota Department of Administration, on behalf of MMCAP, posted RFP S1070000015802 on January 20, 2026, for generic multi-source pharmaceuticals and OTC products across participating state and local facilities in Minnesota and Oregon, with proposals due March 26, 2026, evaluation weighted 75 percent on price competitiveness, and a two-year contract term with optional extensions. The Texas Health and Human Services Commission issued RFI No. HHS0017013 on April 3, 2026, to gather vendor capabilities regarding direct-to-manufacturer prescription programs independent of pharmacy benefit managers and group purchasing organizations, signaling state-level interest in alternative procurement models for pharmaceutical products.